Kund, the company needs to focus and get a couple of wins. If they are doing that then great. Rett results were great but the trials were undersized by 70% - extrapolate out to Trofinetide trial size and it blows T away. Really poor decision by Anavex not to go for the win - they wanted to reduce risk by saving money but they did the opposite. Fragile X 100% should not be started yet. PD...no idea what is going on there but I assume it is, again, due to being focused (or maybe not knowing what path to take, which is what January corporate presentation seems to suggest.)
Market Data 
Markets 
AI
